HOME >> BIOLOGY >> NEWS
Award winners announced for 2001 Merck/AAAS undergraduate science research program

San Francisco, CA 16 February 2001 The Merck Company Foundation and the American Association for the Advancement of Science today announced the names of the 15 universities and colleges that have won awards under the newly expanded program to provide research experiences in chemistry and biology for undergraduate students.

"Each award is worth $20,000 a year for up to three years, and we expect the funds to be used to build bridges between two crucial areas of science -- chemistry and biology," said Shirley Malcom, head of Education and Human Resources at AAAS. "Liberal arts colleges have played a key role in developing leaders in the sciences, and that is why we focus on those institutions."

The purpose of the program is to enhance undergraduate biology and chemistry education through undergraduate research experiences that emphasize the relationship between these scientific fields and to encourage students to pursue graduate education. In addition to supporting the undergraduates research efforts, the awards may provide funding for symposia, lecture series and workshops.

The Merck/AAAS program was launched in 1993 and, until this year, was limited to 12 northeastern/mid-Atlantic states. In 2001, however, the program was opened up to institutions around the country. The Merck Company Foundation has agreed to continue funding 15 awards each year through 2009.

This years winners are California State University in Sacramento, CA; Westminster College in New Wilmington, PA; Pacific Lutheran University in Tacoma, WA; Hobart and William Smith Colleges in Geneva, NY; Hope College in Holland, MI; Oakland University in Rochester, MI; Saint John's University in Collegeville, MN; St. Lawrence University in Canton, NY; St. Olaf College in Northfield, MN; State University of New York College at Fredonia in Fredonia, NY; University of South Alabama in Mobile, AL; University of Tennessee in Chattanooga, TN; University of Wisconsin in Superior, WI
'"/>

Contact: Cate Alexander
calexand@aaas.org
202-326-6431
American Association for the Advancement of Science
15-Feb-2001


Page: 1 2 3

Related biology news :

1. Gladstone investigator Mike McCune wins prestigious NIH Directors Pioneer Award
2. UT Southwestern biochemist honored with NIH Directors Pioneer Award
3. Award winning researchers reveal potential new role for Glivec
4. UMaine anthropologist wins Solon T. Kimball Award
5. Secretary of Energy announces seven E.O. Lawrence Award Winners
6. Martin Saunders to receive the James Flack Norris Award
7. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
8. NJIT professor receives Presidential Award for breakthrough research with adult stem cells
9. Second call for proposals for the European Young Investigator Award
10. Virginia Tech professor honored with DeLaval Award
11. Institute for OneWorld Health nominated for the 2004 World Technology Awards

Post Your Comments:
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... 2015 Veolia’s environmental monitoring technology ... American distribution agreement with VWR to distribute TECTA™ ... more than 160 years of experience, VWR, a ... laboratory and production facilities, has cultivated a value ... services to enable science. Endetec’s TECTA™ B16, ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
(Date:5/20/2015)... -- Health eCareers, the healthcare industry,s online career hub, ... looking for the flexibility of short-term assignments through ... tool dedicated exclusively to temporary and shift work ... employers to quickly find and hire experienced professionals ... other temporary positions, eliminating the time and resources ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
Cached News: